There are currently 65 clinical trials in Webster, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Center for Clinical Studies, Tranquil Clinical Research, Center of Reproductive Medicine and Center for Clinical Studies, LTD. LLP. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
NCT05865041
Recruiting
The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: 1 Site, Webster, Texas
Conditions: Alopecia Areata
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Texas Digestive Disease Consultants - Bay Area Houston Endoscopy Center, Webster, Texas
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 16, Webster, Texas
Conditions: FSGS
Register for Updates
XTX101 Monotherapy and XTX101 and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
NCT04896697
Recruiting
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of XTX101 as monotherapy and XTX101 and atezolizumab combination therapy in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/24/2023
Locations: Tranquil Clinical Research, Webster, Texas
Conditions: Advanced Solid Tumor
Register for Updates
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
NCT05157763
Recruiting
This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma. In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2021
Locations: Center for Clinical Studies, LTD. LLP, Webster, Texas
Conditions: Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Register for Updates